期刊文献+

过氧化物酶体增殖物激活受体γ在人垂体腺瘤中的分布和表达

Distribution and Expression of Peroxisome Proliferator Activated Receptor γ in Human Pituitary Adenomas
下载PDF
导出
摘要 目的研究过氧化物酶体增殖物激活受体γ(PPAR-γ)在人垂体腺瘤组织中的分布和表达。方法免疫组织化学染色检测PPAR-γ在垂体腺瘤组织中的分布情况,Western blot方法分析PPAR-γ在正常垂体与垂体腺瘤中的表达水平。结果免疫组织化学染色显示,PPAR-γ主要分布于细胞核内。Western blot结果显示,PPAR-γ在垂体腺瘤中的表达水平显著高于正常垂体组织(P<0·01),在促肾上腺皮质激素腺瘤中的表达水平显著高于其他内分泌类型垂体腺瘤(P<0·05)。结论PPAR-γ可能在肿瘤的发生、生长、侵袭中起重要作用,该受体有可能成为未来垂体腺瘤治疗的新靶点。 Objective To evaluate the distribution and expression of peroxisome proliferator activated receptor γ (PPAR-γ) in human pituitary adenomas. Methods Thirty eight consecutive surgically resected pituitary adenomas and 5 normal pituitary tissues were enrolled in the study. Immunohistochemistry was used to confirm the distribution of PPAR-γ. Expression of PPAR-γ was evaluated by Western blot. Results PPAR-γ immunoreactivity was located in the nucleoli of pituitary adenoma cells. PPAR-γ was expressed in all human pituitary adenomas and normal pituitary tissues. Its expression in pituitary adenomas was significantly higher than in normal pituitary tissues ( P 〈 O. 01 ) , and its expression in ACTH-secreting adenomas was significantly higher than in any other type of pituitary adenomas ( P 〈 0. 05 ). Conclusions PPAR-γ may play an important role in the generation, growth, and invasion of human pituitary adenomas. It may become a novel therapeutic target for these tumors.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2006年第3期375-377,i0008,共4页 Acta Academiae Medicinae Sinicae
关键词 过氧化物酶体增殖物激活受体Γ 垂体腺瘤 分布 表达 peroxisome proliferator activated receptor γ pituitary adenoma distribution expression
  • 相关文献

参考文献8

  • 1Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature,1990, 347(6294) :645-650.
  • 2Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol, 1999, 10(6):564-570.
  • 3Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med, 1998, 4(9) :1046-1052.
  • 4Ohta K, Endo T, Haraguchi K, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab, 2001, 86(5):2170-2177.
  • 5Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPAR gammal fusion oncogene in human thyroid carcinoma. Science, 2000,289 (5483) : 1357-1360.
  • 6Shimizu M, Saitoh Y, Itoh H. Immunohistoehemieal staining of Ha-ras oneogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol, 1990, 21 (6) :607-612.
  • 7Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest,2003, 111 (9):1381-1388.
  • 8Heaney AP, Femando M, Yong WH, et al. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med, 2002, 8 ( 11 ) : 1281-1287.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部